[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.161.216.242. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 397
Citations 0
Comment & Response
October 28, 2013

Glucagon-like Peptide 1–Based Drugs and Pancreatic Safety

Author Affiliations
  • 1Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy
JAMA Intern Med. 2013;173(19):1843. doi:10.1001/jamainternmed.2013.8150

To the Editor More than 4 years after the first description of exenatide-related pancreatitis, the recent study by Singh et al1 reports a 2-fold increased risk of hospital admission for acute pancreatitis with glucagon-like peptide 1 (GLP-1) mimetics, compared with other antidiabetics.1 The study has immediately fuelled the debate on this topic,2 but a different design is definitely needed to fully elucidate this issue in a more comprehensive clinical perspective.

First Page Preview View Large
First page PDF preview
First page PDF preview
×